Table 1.
Aptamers obtained by in vitro selection currently in clinical trials or approved for their use as therapeutic drugs. Updated June 2009.
| Therapeutic target | Aptamers | Type | Disease indication | Clinical status | Reference |
|---|---|---|---|---|---|
| VEGF | MacugenTM (Pegaptanib Sodium) | 2’-Fluoro- 2’-O-methyl RNA+PEG | Macular degeneration | Market | [57,58] |
| Von Willebrand factor | ARC1779 | DNA/RNA+PEG | Thrombotic microangiopathy Adjunct to carotid endarterectomy | Phase 2 Phase 2 |
[59,60] |
| Factor IXa | REG-1 (RB006 aptamer + RB007 antidote) | RB006 2’-Fluoro RNA+PEG and RB007 2’-O-methyl RNA | Coronary artery bypass Percutaneous coronary intervention | Phase 2 Phase 2 |
[61,62,63] |
| Nucleolin | AS1411 | DNA | Acute myeologenous leukemiaRenal cell carcinoma | Phase 2 Phase 2 |
[64,65,66] |
| PDGF-b | E10030 | DNA | Macular degeneration | Phase 1 | [67,68] |
| Complement factor 5 | ARC1905 | 2’-Fluoro RNA | Macular degeneration | Phase 1 | [69] |
| Thrombin | NU172 | DNA | Coronary artery bypass | Phase 1 | [70,71,72] |
VEGF = vascular endothelial grow factor; PDGF-b = Platelet-derived growth factor B-chain; PEG = polyethylene glycol.